Pheochromocytoma and paraganglioma (PPGL) · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | None |
| ID | IND-SDHB-CARRIER-INTENSIFIED |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-20 | pending_clinical_signoff |
| Diseases | DIS-PHEOCHROMOCYTOMA |
| Sources | SRC-ENDOCRINE-SOCIETY-MEN-2023 SRC-NCCN-NET-2025 |
Notes
STUB — v0.3 gene-specific PGL4 (SDHB) further-intensified surveillance track. Sibling — IND-SDHB-CARRIER-SURVEILLANCE (standard intensive track). CRITICAL severity inherited from RF. §15.2 C4 ≥2-tracks invariant.
Used By
Indication
IND-SDHB-CARRIER-SURVEILLANCE- IND-SDHB-CARRIER-SURVEILLANCE
Red flag
RF-SDHB-SPECIFIC-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in SDHB (succinate dehydrogenas...